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Abstract
Decavanadate compounds were described to be involved in a variety of biological activities and 
responses such as anti-virus, anti-bacterial and anticancer. While the mechanisms of action of the anti-
viral and anti-bacterial activities are better understood, the same does not go for the anti-tumour activity. 
Nevertheless, the inhibition of tumour proliferation seems to impact certain enzymes such as alkaline 
phosphatase, ecto-nucleotidases or P-type ATPases. In the present report, several studies are described, 
in a way to explain the increasing interest of these polyoxometalate in cancer therapy. The detailed 
knowledge of the molecular basis of decavanadate–proteins and cellular interactions allows to better 
understand the processes associated with the anticancer applications, not only for decavanadate but as 
well for other polyoxometalates (POMs).
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Cancer incidence is growing every year all around the 
world, as well as the resistance of already used metal drugs 
like cis-platin. Indeed, in 2012 the global burden of cancer 
rose to 14,1 million of new cases and 8,2 millions of death 
per cancer comparing with 12,7 million and 7,6 million 
respectively in 2008. The most frequent diagnosed cancers in 
the world are the pulmonary one (1,8 million cases, i.e. 13,0% 
of the total), the breast one (1,7 million, i.e. 11,9%) and the 
colorectal one (1,4 million cases, i.e. 9,7%). Due to the global 
aging and the population growth, it was estimated that in 2025 
there will be a substantial increase of new case of cancer per 
year of 19,3%. Besides the effectiveness and resistance effect, 
chemotherapeutic agents, as cisplatin or gemcitabine, are 
also known for their high toxicity. Taking this into account, 
polyoxometalates have been selected by some researchers as 
alternative anti-tumour substances with promising results in 
tumour growth suppression [1-11].
Polyoxometalates are interesting compounds possessing a 
rich diversity of structure and size with large redox chemistry 
and a high solubility in aqueous solutions. Thanks to these 
properties and others, POMs are studied and used in a large 
scale of fi elds, and have become of a great interest in medicine. 
Indeed many polyoxometalates have proved to be effi cient 
against virus, bacteria and tumour cells. Polyoxometalates 
(POMs) are inorganic oligomeric assemblies of transition-
metal (such as vanadium, molybdenum, tungsten) and oxygen 
atoms. Examples of POM’s structure includes Lindqvist (isopoly 
compound), Anderson (hetero atoms on the surface), Keggin 
(hetero atom in the core), Wells-Dawson (2 hetero atoms) and 
Preyssler (various kind of hetero atoms). The Lindqvist type 
of POMs, such as decavanadate (V10) (Figure 1), as well as the 
Dawson type are known for their biological activities against 
virus, bacteria and more recently against tumour cells but 
recently others POMs types are of increasing interest in several 
areas of research [1-11]. 
 Decavanadate anti-cancer activities
Vanadium is a trace element widely distributed in plants 
and animals although its essential role for humans is yet to 
be clarifi ed. Vanadium impact in biology, pharmacology and 
medicine is well known, mainly after the discovery that the 
“muscle inhibitor factor”, present in ATP obtained from horse 
Figure 1: Structural representation of decavanadate species.V10O286-. The red 
spheres represent oxygen atoms.
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muscle and responsible for Na+, K+-ATPase inhibition was, 
in fact, vanadate [12]. Vanadate is also known as a potent 
inhibitor of protein tyrosine phosphatases, described as one 
the main targets of vanadate as an insulin enhancement agent, 
promoting an increasing of glucose uptake in several types of 
cells, among others effects that prevent diabetes [13]. 
Decavanadate, an oligomer with 10 octahedral vanadium(V) 
centres (V10O28
6-), exerts numerous physiological roles, not 
only in vitro, but also in vivo, and is known to interact with a 
wide range of biomolecules [14,15]. Besides the insulin mimetic 
behavior, decavanadate and decavanadate compounds were 
described to be involved in a variety of biological activities and 
responses such as anticancer, anti-bacterial and anti-virus 
[16-20]. In the last years, several papers have been published 
regarding the anti-tumour activity of decavanadate [8,19,20]. 
The most cited paper regarding to decavanadate (V10) 
in biology is the interaction of V10 in a spatially selective 
manner within the protein cages of virions [18]. It seems that 
polyoxometalates (POMs) such as decavanadate are able to 
inhibit the virus activities by preventing the virus-cell host 
binding [18]. However, the anti-tumour activity of decavanadate 
is less understood and more recent than the anti-viral one. 
In 2010, Li et al., synthesized two decavanadates compounds 
and tested their anti-tumour activity in vitro against human 
lung carcinoma cells (A549) and murine leukaemia cells 
(P388) [8]. Both compounds exhibited lower inhibition than 
cis-platin compounds, whereas the decavanadate compound 
with a higher lipophilic effect, thus enhancing its penetration 
through the lipid bilayer of the cell membrane, showed higher 
inhibitory activity [8]. Others decavanadate complexes were 
showing apoptotic mechanism of cell death and also lower 
activities than platin compounds [8,19,20]. 
Abnormal levels of alkaline phosphatase (ALP) in the 
serum are detected in cancer patients since tumours are 
abnormal cellular growth proliferating faster than a normal 
cell [21]. Inhibition of ALP will affect tumour cell metabolism 
and function. Decavanadate species were recently described as 
stronger inibitors of phosphatases such as ALP. Decavanadate 
and others POMs were assessed for their inhibitory effect 
on ALP and as putative anti-tumour agent [22], and results 
demonstrated more than 70% inhibition on intestinal alkaline 
phophatase. Therefore, decavanadate demonstrated inhibition 
on several alkaline phosphatases, suggesting that decavanadate 
similarly to others POMs, inhibit abnormal cellular growth.
Decavanadate and POMs in the future of cancer 
therapy
As cancer incidence is growing every year all around the 
world it has become crucial to fi nd drugs with low toxicity 
and high effi ciency on normal and tumour cells, respectively. 
Polyoxometalates such as decavanadate are interesting 
compounds possessing a rich and diversity biochemistry 
that have become of a great interest in medicine in the last 
years. Indeed many polyoxometalates have proved to be 
effi cient against virus, bacteria and tumour cells. Although 
the mechanism of action of decavanadate complexes and 
species as anti-tumour agent is not yet fully understood, the 
decavanadate effects on tumor proliferation might, at least 
in part, be due to the inhibition of certain enzymes such as 
alkaline phosphatases, ecto-nucleotidases as well as P-type 
ATPases. The detailed knowledge of the molecular basis of 
decavanadate–proteins and cellular interactions will allowed to 
better understand the processes associated with the anticancer 
applications of decavanadate as well as for others POMs.
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